Trial · NCT07886710
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AEs | From the Start of Dosing Through Week 32 | including Adverse events defined by CTCAE 6.0(Common Terminology Criteria for Adverse Events version 6.0) |
| Secondary | Tss_max | From Week 1 to Week 32 | The time required to reach the maximum concentration of EB070 in the bloodstream after administration at steady state. |
| Secondary | Css_max | From Week 1 to Week 32 | The maximum concentration of EB070 in the bloodstream during a dosing interval at steady state. |
| Secondary | Css_min | From Week 1 to Week 32 | The minimum concentration of EB070 in the bloodstream during a dosing interval at steady state. |
| Secondary | AUCss 0-t | From week 1 to week 32 | The area under the concentration-time curve of EB070 from the start to the last measurable concentration during a dosing interval at steady state. |
| Secondary | AUCss 0-∞ | From week 1 to week 32 | The area under the concentration-time curve of EB070 from the start of a dosing interval to infinity at steady state. |
| Secondary | RAUC | From week 1 to week 32 | The ratio of EB070 exposure after repeated dosing to that after a single dose. |
| Secondary | RCmax | From week 1 to week 32 | The ratio of the maximum EB070 concentration after repeated dosing to that after a single dose. |
| Secondary | CL/Fss | From week 1 to week 32 | The apparent clearance of EB070 from the bloodstream at steady state. |
| Secondary | Vz/Fss | From week 1 to week 32 | The apparent volume of distribution of EB070 at steady state. |
| Secondary | Kelss | From week 1 to week 32 | The elimination rate constant of EB070 at steady state. |
| Secondary | t½ss | From week 1 to week 32 | The time required for the concentration of EB070 in the bloodstream to decrease by 50% at steady state. |
| Secondary | MRT | From week 1 to week 32 | The mean residence time of EB070 in the body. |
| Secondary | CLR | From week 1 to week 32 | The renal clearance of EB070. |
| Secondary | FeNO | Baseline; Weeks 5, 9, 13, 17, and 21 | |
| Secondary | Eosinophil Count | Baseline; Weeks 5, 9, 13, 17, and 21 | |
| Secondary | IL5 Concentration | Baseline; Weeks 5, 9, 13, 17, and 21 | |
| Secondary | IL-13 Concentration | Baseline; Weeks 5, 9, 13, 17, and 21 | |
| Secondary | IgE Concentration | Baseline; Weeks 5, 9, 13, 17, and 21 | |
| Secondary | Change from baseline in pre-bronchodilator (Pre-BD) forced expiratory volume in 1 second (FEV1) measured before dosing at each assessment time point | Weeks 5, 9, 13, 17, and 21 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07886710/registered